Cubist Systematic Strategies’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-15,910
| Closed | -$25.3K | – | 4303 |
|
|
2024
Q1 | $25.3K | Buy |
+15,910
| New | +$23.6K | ﹤0.01% | 3455 |
|
|
2023
Q4 | – | Sell |
-34,089
| Closed | -$36.5K | – | 4230 |
|
|
2023
Q3 | $36.5K | Buy |
+34,089
| New | +$70.5K | ﹤0.01% | 3054 |
|
|
2023
Q2 | – | Sell |
-67,793
| Closed | -$277K | – | 4498 |
|
|
2023
Q1 | $277K | Sell |
67,793
-71,223
| -51% | -$329K | ﹤0.01% | 3045 |
|
|
2022
Q4 | $698K | Buy |
139,016
+64,018
| +85% | +$401K | ﹤0.01% | 2764 |
|
|
2022
Q3 | $981K | Sell |
74,998
-106,988
| -59% | -$1.62M | 0.01% | 2639 |
|
|
2022
Q2 | $2.33M | Buy |
181,986
+100,816
| +124% | +$1.4M | 0.01% | 1704 |
|
|
2022
Q1 | $1.24M | Buy |
81,170
+20,464
| +34% | +$319K | 0.01% | 1870 |
|
|
2021
Q4 | $1.07M | Buy |
60,706
+21,422
| +55% | +$411K | 0.01% | 1857 |
|
|
2021
Q3 | $826K | Buy |
39,284
+18,464
| +89% | +$406K | 0.01% | 1670 |
|
|
2021
Q2 | $411K | Buy |
20,820
+8,069
| +63% | +$189K | ﹤0.01% | 2134 |
|
|
2021
Q1 | $371K | Buy |
12,751
+10,821
| +561% | +$303K | ﹤0.01% | 2134 |
|
|
2020
Q4 | $58K | Sell |
1,930
-6,818
| -78% | -$149K | ﹤0.01% | 2455 |
|
|
2020
Q3 | $139K | Sell |
8,748
-8,516
| -49% | -$155K | ﹤0.01% | 2227 |
|
|
2020
Q2 | $341K | Buy |
17,264
+16,256
| +1,613% | +$311K | 0.01% | 1800 |
|
|
2020
Q1 | $12K | Buy |
+1,008
| New | +$16.5K | ﹤0.01% | 2085 |
|
Cubist Systematic Strategies's NGM Position: Q2 2024 in Review
Cubist Systematic Strategies sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q2 2024, closing a stake of 15,910 shares — an estimated $25.3K sold.
Cubist Systematic Strategies first reported a position in NGM in Q1 2020 and held it in 15 quarters. The position peaked at $2.33M in Q2 2022. 0 funds tracked by Wall St. Rank hold NGM as of Q2 2024.
- Cubist Systematic Strategies reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Cubist Systematic Strategies sold 15,910 NGM Biopharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $25.3K.
- Cubist Systematic Strategies first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q1 2020 and held it in 15 quarters.
- Cubist Systematic Strategies's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $2.33M in Q2 2022.
- 0 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q2 2024.
Based on Cubist Systematic Strategies's 13F filing for Q2 2024, filed 14 Aug 2024.